Twitter | Pretraživanje | |
Frank Vinluan
This drug didn't pan out treating a rare blood disorder or chronic kidney disease. But with positive topline Phs 2 data in , some now see blockbuster potential. shares shot up 50% Tues.
Sotatercept was one of the first compounds to emerge from the labs of Acceleron Pharma, but it became a forgotten piece of the company’s pipeline. Passed
Xconomy Xconomy @Xconomy
Reply Retweet Označi sa "sviđa mi se" More